You are here

Developmental Research Program Grant Recipients

The goal of the SARC Sarcoma SPORE Developmental Research Program is to fund research projects that complement and enhance the research that is essential to the SARC Sarcoma SPORE. Each year we offer new opportunities for researchers to submit ideas when we issue our requests for proposal.

YEAR 4: Funded Projects 2015-2016

DAVID KIRSCH, MD, PHD
YVONNE MOWERY, MD, PHD

Duke University Medical Center
Mechanisms that Regulate Sarcoma Response to Immune Checkpoint Inhibition of PD1

TSZ KWONG “CHRIS” MAN, PHD
Baylor College of Medicine
The Metastatic Role of Lysyl Oxidase in Osteosarcoma

WILLIAM W. TSENG, MD
University of Southern California
Immune Profiling in Well Differentiated/Dedifferentiated Liposarcoma

YEAR 3: Funded Projects 2014-2015

LAURENCE BAKER, DO
University of Michigan
Can heart disease be predicted in young survivors of osteosarcoma using morphomics and/or coronary artery calcium scores?

DAVID KIRSCH, MD, PHD
YVONNE MOWERY, MD, PHD

Duke University Medical Center
Mechanisms that regulate sarcoma response to immune checkpoint Inhibition of PD1

SETH POLLACK, MD
Fred Hutchinson Cancer Research Center
Designing improved T-cell therapies for sarcoma patients

BRIAN RUBIN, MD, PHD
Cleveland Clinic Foundation
Identification of prognostic and therapeutic biomarkers in epithelioid hemangioendothelioma

ANAND SINGH, MD
Massaschusetts General Hospital
Computer-aided estimation of tumor viability fractions on MRI to facilitate procurement of negative surgical resection margins of musculoskeletal sarcoma

YEAR 2: Funded Projects 2013-2014

ZHENFENG DUAN, PHD
Massachusetts General Hospital
Dissecting CDK11 kinase pathway in osteosarcoma

JONATHAN FLETCHER, MD
ADRIÁN MARIÑO-ENRIQUEZ, MD, PHD

Brigham & Women’s Hospital
Biomarkers for Dystrophin-deficiency in sarcoma

CHARLES KELLER, MD
Oregon Health & Science University
DAVID LANGENAU, PHD
Massachusetts General Hospital
GSK3-beta inhibitors for relapsed rhabdomyosarcom

DAVID KIRSCH, MD, PHD
REBECCA DODD, PHD

Duke University Medical Center
Translating discoveries from a mouse model into metastatic biomarker

STEPHEN LESSNICK, MD, PHD
SUNIL SHARMA, MD
University of Utah Huntsman Cancer Institute
Epigenetic targeting of LSD1 as a therapeutic strategy for Ewing sarcoma

BRIAN RUBIN, MD, PHD
Cleveland Clinic Foundation
Identification of prognostic and therapeutic biomarkers in epithelioid hemangioendothelioma

YEAR 1: Funded Projects 2012-2013

ZHENFENG DUAN, PHD
Massachusetts General Hospital
Dissecting CDK11 kinase pathway in osteosarcoma

JONATHAN FLETCHER, MD
ADRIÁN MARIÑO-ENRIQUEZ, MD, PHD

Brigham & Women’s Hospital
Biomarkers for Dystrophin-deficiency in sarcoma

CHARLES KELLER, MD
Oregon Health & Science University
DAVID LANGENAU, PHD
Massachusetts General Hospital
GSK3-beta inhibitors for relapsed rhabdomyosarcoma

DAVID KIRSCH, MD, PHD
REBECCA DODD, PHD

Duke University Medical Center
Translating discoveries from a mouse model into metastatic biomarkers

STEPHEN LESSNICK, MD, PHD
SUNIL SHARMA, MD

University of Utah Huntsman Cancer Center
Epigenetic targeting of LSD1 as a therapeutic strategy for Ewing sarcoma

KEBIN LIU, PHD
Georgia Regents University
RAPHAEL POLLOCK, MD, PHD
Ohio State University
Combined radiosensitization and T cell immunotherapy for metastatic sarcoma